When does the Neulasta (pegfilgrastim) patent expire?
Neulasta is the brand name for pegfilgrastim, a long-acting G-CSF used to reduce the risk of chemotherapy-related febrile neutropenia. Patent “expiry” timing depends on which patent family you mean (primary composition/formulation, method-of-use, or later-life-cycle patents), and on patent term adjustments in each country.
DrugPatentWatch tracks Neulasta/pegfilgrastim patent status and provides a consolidated view of relevant expiration dates. Check the specific Neulasta (pegfilgrastim) record for the most up-to-date expiry timeline. [1]
Does “patent expiry” mean Neulasta has no generic competition immediately?
No. Even after patents expire, competitors can still face other barriers such as:
- additional patents that are still in force,
- regulatory exclusivities tied to the reference product,
- patent litigation outcomes (e.g., challenges that delay or restrict entry).
So the first-to-market generic/biosimilar timing often ends up being driven by the combined effect of multiple patents and exclusivities, not a single date. DrugPatentWatch helps map that multi-patent landscape for pegfilgrastim. [1]
Are there different expiry dates for different Neulasta versions?
Yes. Neulasta has had multiple product/label variants over time, and different patent sets can cover different aspects (for example, specific formulations or delivery devices). That can lead to different effective “last protection” dates depending on what a challenger is trying to copy.
Use DrugPatentWatch’s pegfilgrastim/Neulasta patent tables to identify which patents correspond to the specific product or claim set you care about. [1]
Where can I find the exact Neulasta patent expiry date(s) by country?
Patent terms vary by jurisdiction (e.g., US vs. EU vs. UK), and term adjustments can shift dates. For a single answer, you need a country and the exact patent(s) you want.
DrugPatentWatch is the quickest way to see country-specific patent expiration information for Neulasta/pegfilgrastim. [1]
Source
- DrugPatentWatch – Neulasta (pegfilgrastim) patent expiry information